Skip to main content

McKesson Value Stock - Dividend - Research Selection

Mckesson

ISIN: US58155Q1031 , WKN: 893953

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. This segment also provides specialty pharmaceutical solutions for pharmaceutical manufacturers; and medical-surgical supply distribution, logistics, and other services to healthcare providers. In addition, this segment operates retail pharmacy chains in Europe and Canada, as well as supports independent pharmacy networks in North America and Europe; and supplies integrated pharmacy management systems, automated dispensing systems, and related services to retail, outpatient, central fill, specialty, and mail order pharmacies. This segment serves retail national accounts, including national and regional chains, food/drug combinations, mail order pharmacies, and mass merchandisers; and institutional healthcare providers, such as hospitals, health systems, integrated delivery networks, and long-term care providers, as well as offers its services to pharmaceutical manufacturers. The McKesson Technology Solutions segment provides clinical, financial, and supply chain management solutions to healthcare organizations. McKesson Corporation was founded in 1833 and is headquartered in San Francisco, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

2026-09-18
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Really like Northrop Grumman as a value play, says Regan Capital's Skyler Weinand

2026-09-17
Skyler Weinand, Regan Capital CIO, joins 'Power Lunch' to discuss the best stocks for a sustained rate hike cycle.

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

2026-09-17
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

2026-09-16
McKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.

Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong

2026-09-16
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years

2026-09-15
McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 23.05% on an annualized basis producing an average annual return of 34.83%. Currently, McKesson has a market capitalization of $104.88 billion.

Did McKesson’s (MCK) EPS Hike and Oncology Push Just Redefine Its Investment Narrative?

2026-09-15
McKesson recently raised its full-year EPS guidance, projecting approximately 13%–15% growth (15%–17% excluding certain prior-year items), and outlined plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO targeted for the second half of 2027, alongside a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. This combination of upgraded earnings expectations, portfolio reshaping around...

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

2026-09-14
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

2026-09-14
McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

2026-09-14
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.